Radiotherapy for cancers of the oesophagus, cardia and stomach.

Fiche publication


Date publication

décembre 2021

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RETIF Paul


Tous les auteurs :
Créhange G, Modesto A, Vendrely V, Quéro L, Mirabel X, Rétif P, Huguet F

Résumé

We present the updated recommendations of the French society for radiation oncology on radiotherapy of oesophageal cancer. Oesophageal cancer still remains a malignant tumour with a poor prognosis. Surgery remains the standard treatment for localized cancers, regardless of histology. For locally advanced stages, surgery remains a standard for adenocarcinomas after neoadjuvant treatment with chemotherapy or chemoradiotherapy. However, it is a therapeutic option after initial chemoradiotherapy for stage III squamous cell carcinomas, given the increased morbidity and mortality with a multimodal treatment, which results in an equivalent overall survival with or without surgery. Preoperative or exclusive chemoradiotherapy should be delivered according to validated regimens with an effective total dose (50Gy), if surgery is not planned or if the tumour is deemed resectable before chemoradiotherapy. Intensity-modulated radiotherapy significantly reduces irradiation of the lungs and heart and may reduce the morbidity of this treatment, especially in combination with surgery. In case of exclusive chemoradiotherapy, dose escalation beyond 50Gy is not currently recommended. Some technical considerations still remain questionable, such as the place of prophylactic lymph node irradiation, adaptive radiotherapy, evaluation of response during and after chemoradiotherapy and the value of proton therapy.

Mots clés

Cancers de l’œsophage, Chemoradiotherapy, Chimioradiothérapie, French society for radiation oncology, Guidelines, Oesophageal cancer, Radiation therapy, Radiothérapie, Recommandations, Société française de radiothérapie oncologique.

Référence

Cancer Radiother. 2021 Dec 22;: